[MPXFollower]

"$ianthus sent out a “heads up” the good news will be out on the 20th PR this morning ..... looked loke a word to the wise memo to me.... buy buy buy"

Was the above written by a toddler?

Your post is useless here. As are you.
Post this in the IANTHUS section where it belongs.

Now do you chores, collect your allowance and go back into your mother's basement... But don't worry, she really is proud of you.

[IMACMAN]

Really?..... ok let me simplify this “for you”..... the purpose for my original post was simple..... most people that own Ianthus shares.... also own MPX shares..... and good news from MPX is obviously of interest to these share holders why anyone woukd have an issue with that is not clear.

[MPXFollower]

Are you a child?
My point is iAnthus earnings have nothing to do with MPXI.

Make a valid point. Say something that is not blasphemous.

[IMACMAN]

Wtf did i make up??? Most of ianthus share holders alsomown mpx. Pfttttt. Apparently not you. Lol

[Sam Dan]

Significant role out of revenue store opening in England !
"MPXI" or the "Company") (CSE:MPXI; OTC PINK:MPXOF) announces that its UK premium CBD retail experience launched earlier today with the opening of the inaugural "beleaf" store in the Soho district of Central London.
Focused on providing quality, organic and ethically-sourced products in an upscale retail setting, beleaf offers a broad range of premium brand extracts, cosmetics, vapes and edibles with initially more than 100 product lines available for sale. An emphasis on providing education will help counsel CBD curious consumers; physical in-store displays, digital kiosks and online resources will be complemented by on-site cannabis specialists available to address queries and help guide purchasing decisions. The location also features a ‘blends bar' and lounge where customers can sample various CBD-infused products.

"This first beleaf store is an escalation of our mission to be trailblazers of CBD access in the UK, European Union and globally. Our dedication to providing quality products and building brand equity through this venue will enable us to capture meaningful market share in a nascent market on the verge of massive growth," said W. Scott Boyes, Chairman, President and CEO of MPXI. "We are creating a first-mover advantage that positions MPXI for success as a global player in the medical and adult-use cannabis markets by creating a retail "go-to" brand in beleaf. With a population of more than 66 million and another 36 million tourists visiting annually, the UK is the perfect place to launch this exciting venture."

MPXI is working in partnership with the renowned retail developer, iD agency, known for bringing consumers retail experiences for brands such as Nespresso, Pepsi and L'Oreal. With extensive experience creating and managing unique, effective and immersive retail environments, iD agency will manage the beleaf store and promotional events.

"We saw a lot of confusion and misinformation in the CBD space, with very little product quality control, and so our mission from the start was to educate and build consumer confidence as a leading authority on CBD in Europe," said Daniel Fryer, Director of European Development at MPXI. "As a result of our international reach, we have encountered some exceptional brands across the globe that we are excited to offer our UK customers. Following the launch of our London shop, we have plans to open additional outlets and shop-in-shops across Europe next year."

Research from the Centre for Medicinal Cannabis estimates that the UK CBD market reached £300 million this year and could grow to £1 billion by 2025 - a value larger than the markets for Vitamin C and Vitamin D combined. CBD is currently available in 27 other European countries.

About beleaf

Located at 19 D'Arblay St, Soho W1F 8ED.

Hours of operation: Mon-Sat 10.00am-7.30pm. Sun 11.00am-5.00pm

Tel: [phone]

About MPX International Corporation

MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

[MPXFollower]

So you made an assumption that iAnthus will make an announcement regarding MPX on the 20th.

What relationship do they have now? They are separate entities.
You realize iAnthus is pursuing CBD opportunities in Europe which do NOT include MPX.

What concrete info do you have? Or only fables?

I am a believer in both companies, but I am not going to come here and make stuff up.

[IMACMAN]

I am one of the share holders that got MPX shares from the ianthus spinoff there is a relationship between the two.

[MPXFollower]

What does the iAnthus PR have to do with MPX?

[MPXFollower]

What does iAnthus have to do with MPX's operations???

[IMACMAN]

Excellent news just out MPX has received the approval from Australias Govt for their production license, nice big brand new facility going up will be ready mid 2020..... great strategic location globally thats well suited to servicing the market geographically. This is awesome news, slow and steady wins the race, build out the infrastructure world wide and MPX will quickly have positioned themselves to be a Global Leader in this huge immerging market. Congrats MPX great strides!... Now let the world know YOU are Coming!

[IMACMAN]

$ianthus sent out a “heads up” the good news will be out on the 20th PR this morning ..... looked loke a word to the wise memo to me.... buy buy buy

[Sam Dan]

Nice to see Board members buying shares

""MPXI" or the "Company") (CSE:MPXI)(OTCPINK:MPXOF) today announced that W. Scott Boyes, Chairman, CEO and President of MPXI, and Randall Stafford, a Director of MPXI, have, during the month of October 2019, executed open-market purchases of an aggregate of 1,271,000 common shares of MPXI (the "MPXI Shares") for the aggregate purchase price of CDN$597,094.

Mr. Boyes purchased 800,000 MPXI Shares with an average cost of CDN$0.482 per MPXI Share for a total purchase amount of CDN$385,788. Mr. Stafford has acquired 471,150 MPXI Shares at an average of CDN$0.448 per MPXI Share for a total purchase price of CDN$211,306.

"We continue to be very excited about the rapidly emerging global medical cannabis marketplace," commented Mr. Boyes. "With over 35 countries having now legalized medical cannabis, the industry is entering a phase of rapid international expansion and, as MPXI continues to develop its operations in the UK, Malta, Switzerland, Australia, South Africa, Canada and elsewhere, I am ever-more confident that our company is well-positioned for near-term growth and profitability and for the creation of long-term value for its shareholders."

[MPXFollower]

JOIN THE FACEBOOK GROUP. ITS MORE ACTIVE

[Sam Dan]

me

[IMACMAN]

Does anyone follow this board?..., anyone??....at all???

[Sam Dan]

Significant addition to management

"MPXI" or the "Company") (CSE:MPXI)(OTC:MPXOF) has announced the appointment of former Director of Reynolds-American Inc. Jean-Marc Lévy to its Advisory Board. Reynold-American was the 2nd largest tobacco company before being acquired by British American Tobacco (BAT) in 2017.
Mr. Lévy also served on the Management Board of BAT PLC where he directed its marketing and sales functions as Group Chief Marketing Officer from 2009 until 2014. A multilingual business leader with a successful track record of consumer-centric strategy, brand-building and operational delivery, Jean-Marc will help develop and lead strategic business development opportunities for MPXI. Mr. Lévy is also an Executive-in-Residence at the IMD School of Business in Lausanne, Switzerland.
"The addition of a seasoned tobacco executive such as Jean-Marc to our advisory board is a reflection of our strengthening market position and the long-term potential of MPXI," said W. Scott Boyes, Chairman, President and CEO of MPXI. "We anticipate that Jean-Marc's significant relevant business development experience and expertise will prove invaluable as we work to execute on our global growth strategy."

"The medical cannabis industry is ripe with opportunity and I am excited to align myself with MPXI to help lead and drive strategic business development opportunities," said Jean-Marc Levy. "The company's previous strong track record of success in the US, highly experienced management team and the significant progress they've made since the beginning of this year were just a few of the aspects that drew me to work with this globally-oriented growth story."

Additionally, MPXI has announced the appointment of Karl Bartolo as General Manager of its operations in Malta, where the company recently acquired a GMP-ready facility that will become the hub of its European medical cannabis production capacity. With significant experience leading and managing strategic and operational performance, Mr. Bartolo will oversee the refurbishment of the facility and help facilitate the GMP certification process.

Karl comes to MPXI with a Master's Degree in Industrial Pharmacy, an Advanced Lean Sigma 6 Green Belt and over 10 years of experience in pharmaceutical quality control and general management.

"Mr. Bartolo's familiarity with EU-GMP and his regional regulatory expertise in Malta is expected to help expedite the completion of our site refurbishment and the licensing process there," continued Mr. Boyes. "These are exciting times for MPXI and these additions to our team make us even stronger as we work towards our revenue and profitability goals in Europe."

[Sam Dan]

Nice news for a change "(CSE:MPXI; OTC PINK:MPXOF) today announced that its wholly-owned subsidiary, Canveda Inc. (“Canveda”) has achieved Gold Status in its bQb-cert Good Manufacturing Practice (“GMP”) and Quality System Compliance Audit at its 12,000 square foot facility located in Peterborough, Ontario, where it produces high quality cannabis flower. Achieving GMP certification demonstrates MPXI’s commitment to quality and safety in cannabis manufacturing and is an important milestone in the Company’s international growth strategy.

MPXI is strategically positioned to pursue opportunities in the emerging global cannabis marketplace and plans to use its cannabis assets in Canada as a base to export to targeted international markets. Securing bQb-cert GMP certification at its Ontario production facility ensures that MPXI’s products are consistently produced and controlled according to Canada’s highest regulatory standards, enabling the Company to start exporting its products to Australia and other markets. The Company is also working toward EU GMP certification, to facilitate the export of its products to the European Union.

“With a score of 97.7%, achieving this certification proves we have best in class production standards, software and record keeping. As the international markets continue their march towards legalization of cannabis, GMP certification in Canada is more important than ever as it will allow us to immediately use our Canveda facility as a portal to export our products internationally,” said W. Scott Boyes, Chairman, President and Chief Executive Officer of MPXI. “As part of our international strategy, we are also working toward authorization to export to the European Union, which has the strictest cannabis GMP standards in the world, while also developing our international assets in Switzerland, Malta and elsewhere. Furthermore, on a national scale, GMP status also provides our Canadian medical cannabis patients with strong quality control assurance, further setting Canveda and its products apart.”

Canveda continues to develop different strain varieties and recently received its final sales licence enabling it to sell fresh and dried cannabis directly to medical patients, provincial and territorial cannabis boards and other licensees holding a licence to sell for medical purposes.

About MPX International Corporation

MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

[Sam Dan]

A significant move by management opens up EU as potential major source of revenue

" (CSE:MPXI) (OTC Pink:MPXOF) is pleased to announce that MPXI Malta Property Ltd. (“MPXI Malta”), a Maltese-company owned by MPX International (80%) and Malta-based Bortex Group (“Bortex”) (20%) has completed the acquisition of all the outstanding shares of Alphafarma Operations Ltd. (“Alphafarma”) from Alpha Farma Limited (the “Vendor”).

The Vendor, which is in the business of acquiring, repackaging and distributing pharmaceutical products throughout the European Union and North Africa, has transferred the lease for the “GMP-ready” facility located in Mehriel, just outside of Valletta, the capital city of Malta, as well as the GMP certification to Alphafarma, the newly created subsidiary of the Vendor, in exchange for the payment of €1.5 million (approximately CDN$2,260,800) in cash and the issuance of 1,000,000 common shares (“MPXI Shares”) and 300,000 common share purchase warrants to acquire additional MPXI Shares at an exercise price of $0.63 per MPXI Share for a period of five (5) years.

MPXI Malta has been awarded a letter of intent from Malta Enterprise, the economic development agency for the Republic of Malta, to receive a license to import, extract, produce finished products and distribute cannabis and cannabis derivatives (the “Malta License”) for medicinal use in Malta and export to certain international markets, in particular the European Union.

The Malta License will be issued by the Malta Medicines Authority upon completion and EU-GMP certification of a cannabis processing facility. Upon receipt of the formal Malta License, MPXI will produce EU-GMP quality cannabis oils and cannabis derivative products and pursue regulated medical cannabis distribution opportunities in the European Union through Salus BioPharma.

Select employees from the current tenant of the facility, several of which are experienced and certified in the various quality control and quality assurance standards required for EU-GMP production will remain with MPXI. The availability of such qualified personnel will also shorten and facilitate the GMP certification process and allow MPXI to more quickly secure final license approval and commence operations.

The Company is expected to invest approximately €3.0 million (approximately CDN$4,521,600) for refurbishing the facility, extraction, processing and packaging equipment and working capital.

The Company issued to Green Goblin Ventures Limited (“Green Goblin”) 555,375 MPXI Shares as consideration for the preparation of the application for the License and 142,484 MPXI Shares as consideration for identifying and facilitating the acquisition of Alphafarma.

As part of the partnership agreement whereby Bortex will provide oversight of and support to MPXI’s Maltese operations and as consideration for assistance with setting up the local manufacturing facility in the newly acquired Alphafarma site, the Company issued to Bortex 836,375 MPXI Shares. Bortex, a well-established Maltese conglomerate involved in manufacturing, distribution, retail operations and property development, will provide local support and oversight of the Company’s Malta operations.

[Sam Dan]

Significant milestone for the company


" (“MPX International”, “MPXI” or the “Company”) (CSE:MPXI; OTC:MPXOF) is pleased to announce that Canveda Inc. (“Canveda”), a wholly-owned subsidiary of MPXI, has received approval from Health Canada to sell Cannabis, effective as of July 26, 2019, in accordance with Sections 11(5), 17(5) and 27 of the Cannabis Regulations pursuant to an application to amend the conditions of its previously obtained licence for standard cultivation to allow for the sale of fresh and dried cannabis products.

In addition to sales to other Licenced Producers, the amended licence authorizes the sale of fresh and dried cannabis:

directly to medical patients;
all of the provincial and territorial cannabis boards; and
holders of a licence for sale.
“The ability to sell into both the recreational and medical cannabis markets in Canada as a result of this amendment represents a significant milestone for Canveda and opens the door to significant growth opportunities that we are ready to capitalize on,” said W. Scott Boyes, Chairman, President and CEO of MPX International. “On the recreational side, we will be able to apply to provincial boards to provide fresh and dried cannabis directly into a high demand market that has been limited by supply constraints. On the medical side, we have a comprehensive growth strategy with all of the required elements in place so that we may begin to immediately execute on our plan to drive patient acquisition, revenue growth and shareholder value.”

The Medical Cannabis Learning Network (the “Medical CLN”) is expected to play a key role in the Company’s sales growth. This turnkey video learning and engagement platform can be accessed by patients via a secure online portal or at in-store kiosks found in medical clinics, pharmacies and the offices of natural health practitioners. Patients wanting to learn about various aspects of medical cannabis, including how products work and which formulations are most appropriate for them, are able to access fact-based information in a safe and compliant manner via the Medical CLN. They are also able to fulfill prescriptions for products from Licenced Producers, including Canveda.

In addition, the Medical CLN will assist Spartan Wellness Corporation (“Spartan”), which provides support services to veterans, with the conversion of its patients to Canveda, enabling better patient adherence and improved patient outcomes. Spartan is a wholly-owned subsidiary of MPXI.

The Canveda facility, located near Peterborough, Ontario, is a fully-licenced 12,000 square foot facility with annual production capacity of 1,200 kilograms.

“We are fully ready to roll out our Medical CLN. Providing people with fact-based information directly personal to them is a unique mechanism that supports patients, facilitates knowledge transfer, and helps drive patient acquisition. With marketing regulations limiting the ways in which to build brand awareness, we believe the Medical CLN is an excellent conduit to capture the attention of new potential medical cannabis patients,” said Michael Arnkvarn, Chief Operating Officer, MPXI Canada. “Furthermore, the CLN will enable us to more fully serve our already strong patient base through Spartan Wellness, which is dedicated to serving the medical needs of Canadian veterans and first responders.”

About MPX International Corporation

MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient."

[Sam Dan]

(CSE: MPXI; OTC PINK: MPXOF) is pleased to announce that it has acquired the remaining interest of MPX Australia Pty Ltd (“MPX Australia”) on July 22, 2019 for a total purchase price of up to $4,000,000 to be satisfied by the issuance of up to 7,145,559 common shares in the capital of MPXI (“MPXI Shares”) as follows: 2,689,189 MPXI Shares ($1,250,000) at a price of $0.46 per MPXI Share upon the granting of the Cannabis License (as defined below) (“Milestone #1”); 2,151,351 MPXI Shares ($1,250,000) at a price of $0.58 per MPXI Share upon the completion of the Launceston Facility (as defined below), being the issue of an occupancy certificate by a governmental entity (“Milestone #2”); and 2,305,019 MPXI Shares ($1,500,000) at a price of $0.65 per MPXI Share upon the earliest of: (i) the first successful harvest; (ii) the first material export; or (iii) immediately prior to the closing or occurrence of a change of control of the Company (“Milestone #3”).In addition, the Company will issue 327,123 MPXI Shares at a price of $0.46 per MPXI Share to satisfy the principal as well as the accrued and unpaid interest on a loan incurred by MPX Australia from the lender in the aggregate amount of $152,054.88 (the “Loan Conversion Amount”).MPX Australia has applied to the Australian Office of Drug Control for a medicinal cannabis license (cultivation and production) in Australia in accordance with the Narcotic Drugs Act 1967 (Cth) (the “Cannabis License”) and is in the process of designing a facility in Tasmania, Australia (the “Launceston Facility”).“The acquisition of the remaining interests in MPX Australia is another milestone for our international expansion strategy that will provide MPX International with access to the growing Australian market and will also serve as our gateway into the Asian markets,” noted W. Scott Boyes, Chairman, President and CEO of MPX International. “With the continued execution of our international expansion plans in 7 international jurisdictions, we are positioning MPX International to lead the international market and drive diverse and sustainable revenue.”About MPX International CorporationMPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.Cautionary Statement Regarding Forward-Looking InformationThis news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise."

[mrd4444mrd]

https://www.bloomberg.com/press-releases/2019-07-16/mpx-international-acquires-20-stake-in-medical-cannabis-learning-network

[mrd4444mrd]

Quiet around here. Let's go Boyes!

[IMACMAN]

This should start moving north.... when word gets out..... pretty big deal here..... but most share holders got their shares from the Ianthus deal...... we need some new outside investors.... this news might do it..... assuming word gets around

[The_Truth_NL]

Deal has been completed:

TORONTO, ONTARIO, April 21, 2019 – MPX International Corporation (“MPX International”, “MPXI” or the “Company”) (CSE:MPXI; OTC:MPXOF) is pleased to announce that it has completed the previously announced acquisition of all of the outstanding shares of HolyWorld SA (“HolyWeed”) from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the “Shareholders”) for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF 1.00) (the “Purchase Price”).

Pursuant to the terms of the definitive agreement, MPXI satisfied the Purchase Price through the issuance of 25,252,830 common shares of MPXI (the “MPXI Shares”) to the Shareholders at price of CDN$0.53 per MPXI Share. 80% of the MPXI shares issued to the shareholders of HolyWeed will be placed in a voluntary escrow to be released to the shareholders upon the occurrence of the following:

1. 20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon the official launch and sale of cannabidiol oil on the HolyWeed eCommerce Platform;

2. 20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of an annualized revenue run-rate of CHF 5,000,000.-; and

3. 40% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of achieved EBITDA of CHF1,600,000.- for the twelve month trailing period.

If the release conditions have not been satisfied by June 30, 2021, any MPXI Shares remaining in Escrow shall be automatically released by the Escrow Agent to MPXI for cancellation.

HolyWeed, which is the only Swiss CBD brand awarded the official ‘Swiss Certified Organic’ label, has a diverse product range which includes 100% Swiss grown cannabis light/high CBD pre-rolls, dry flowers, sublingual oils and cosmetics, all compliant with Swiss regulations of <1% THC. HolyWeed will be harvesting over 25,000 kilograms of high-CBD dry cannabis flowers later this year. HolyWeed’s wholesale distribution network spans more than 4,000 kiosks across Switzerland and will soon expand to wider export markets across Europe. HolyWeed products are also available for sale online and delivered free of charge by courier across Switzerland within 24 hours. HolyWeed also plans to open branded retail stores in Geneva and Zurich.

MPXI will develop a GMP-certified manufacturing facility to produce CBD extracts and isolates for both HolyWeed and export. The facility will feature a full-scale commercial kitchen and a formulation R&D laboratory, giving MPXI the ability to develop innovative CBD products and to potentially collaborate with local partners.

“The acquisition of HolyWeed is a major step in MPX International’s expansion strategy,” stated W. Scott Boyes, MPXI’s Chairman, President and CEO. “HolyWeed brings to our company a well-recognized brand and a solid opportunity to expand into other legal ‘cannabis-light’ markets in Europe.”

About MPX International Corporation

MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

About HolyWeed

Co-founded in 2017 by celebrity Swiss cannabis pioneer Bernard Rappaz, HolyWeed is the only Swiss CBD brand officially ‘Swiss Certified Organic’. HolyWeed has built one of the most professional management teams in the Swiss CBD sector and has demonstrated a strong branding expertise while continuously focusing on innovative product development. Fully verticalized, from seed to sale, Holyweed is one of the largest outdoor CBD cultivators in Western Europe with a highly competitive cost of production. For more information about HolyWeed, please visit www.holyweed.ch.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
T: [phone]
[e-mail]
www.mpxinternationalcorp.com

[nanook2]

I hope no one buys this for awhile. I need to slowly build up my shares.

[The_Truth_NL]

Huge news:

MPX International Acquires HolyWeed, a Swiss Premium Organic Cannabis Company

Wednesday, April 10, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / April 10, 2019 / MPX International Corporation ("MPX International", "MPXI" or the "Company") (CNSX: MPXI; OTC PINK: MPXOF) is pleased to announce that it has entered into a definitive agreement to purchase all outstanding shares of HolyWorld SA ("HolyWeed") from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the "Shareholders"). This acquisition represents a major step in MPXI's expansion strategy, adding a highly recognized brand to its portfolio, as well as one of the largest Western European outdoor cultivators of high-CBD flowers.

Pursuant to the terms of the Purchase Agreement, MPXI will acquire all of the HolyWeed Shares for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF1.00 for the purposes of this resolution which number shall be adjusted upwards or downwards to the extent necessary using the exchange rate posted at the close of business by the Bank of Canada five (5) days prior to closing) through the issuance of common shares of MPXI (the "MPXI Shares") at price of CDN$0.53 per MPXI Share. MPXI will issue approximately 25,252,830 MPXI Shares to the shareholders of HolyWeed which number shall be adjusted upwards or downwards to the extent necessary using the exchange rate posted at the close of business by the Bank of Canada five (5) days prior to closing.

HolyWeed's product range includes 100% Swiss grown cannabis light/high CBD pre-rolls, dry flowers, sublingual oils and cosmetics, all compliant with Swiss regulations of <1% THC. They are the only Swiss CBD brand awarded the official 'Swiss Certified Organic' label and will be harvesting over 25,000kg of high-CBD dry cannabis flowers later this year. HolyWeed's wholesale distribution network spans more than 4,000 kiosks across Switzerland and will soon expand to wider export markets across Europe. HolyWeed products are also available for sale online and delivered free of charge by courier across Switzerland within 24 hours. HolyWeed also plans to open branded retail stores in Geneva and Zurich.
Complementing the acquisition, MPXI will develop a GMP-grade manufacturing facility to produce CBD extracts and isolates for both HolyWeed and export. The facility will feature a full-scale commercial kitchen and a formulation R&D laboratory, giving MPXI the ability to develop innovative CBD products and to collaborate with local partners.

"Switzerland is home to some of the most advanced consumer goods, cosmetics, ingredients and pharmaceutical companies in the world, and HolyWeed being on their doorstep opens a whole host of future opportunities," said Daniel Fryer, MPXI's Head of European Development.

In February of this year, the Swiss government announced plans for a pilot test which would result in temporary licenses for local cannabis companies to produce and sell higher THC marijuana for adult consumer use within a regulated framework. Final details of the program are to be released later this year.

"The acquisition of this exciting Swiss participant in the emerging European cannabis market represents our first foray outside of Canada" noted W. Scott Boyes, MPXI's Chairman, President and CEO. "HolyWeed brings to our company a strong local management team, a well-recognized brand of products and a solid opportunity to expand into other legal 'cannabis-light' markets in Europe."

"Merging HolyWeed with MPXI represents a unique opportunity to leverage our first-mover advantage in Switzerland and to develop our operations internationally with the support, expertise and best-in-class track record of the MPXI management team" remarks Bernard Rappaz, co-founder of HolyWeed. "I am delighted and excited to continue my life long mission to offer to the world the fantastic benefits of cannabis".

Upon closing, 80% of the MPXI shares issued to the shareholders of HolyWeed will be placed in a voluntary escrow to be released to the shareholders upon the occurrence of the following:

20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon the official launch and sale of cannabidiol oil on the HOLYWORLD eCommerce Platform;
20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of an annualized revenue run-rate of CHF5,000,000;
40% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of achieved EBITDA of CHF1,600,000 for the twelve-month trailing period.
If the Release Conditions have not been satisfied by June 30, 2021, any MPXI Shares remaining in Escrow shall be automatically released by the Escrow Agent to MPXI for cancellation.

About MPX International Corporation

MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

About HolyWeed

Co-founded in 2017 by celebrity Swiss cannabis pioneer Bernard Rappaz, HolyWeed is the only Swiss CBD brand officially 'Swiss Certified Organic'. HolyWeed has built one of the most professional management teams in the Swiss CBD sector and has demonstrated a strong branding expertise while continuously focusing on innovative product development. Fully verticalized, from seed to sale, Holyweed is one of the largest outdoor CBD cultivators in Western Europe with a highly competitive cost of production. For more information about HolyWeed, please visit www.holyweed.ch.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International's public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:

MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
T: [phone]
[e-mail]
www.mpxinternationalcorp.com

SOURCE: MPX International Corporation

[Smoothsailor]

He did not say he bought more shares, just that he spent more on the company. He said that the market is international now, and not just focusing locally.

[Rockhall]

MPXOF

[brandao]

What’s the otc ticket for this

[jim8680]

Since when? I have not seen an insider buy? Are you sure Scott bought a million shares?

[pinhigh]

OK..just realized it's the US/Canada exchange rate. Dah

[pinhigh]

Smoothsailor..maybe you know. I was awarded some mpxi shares in my Schwab account after the merger. Schwab uses the symbol mpxof instead of mpxi. Also the pps is not matching up. (.51 vrs .68 currently) Would you happen to have an explanation for these discrepancies? Thanks to you or anyone who might have an explanation.

[Smoothsailor]

Talked to Scott and he told me he put plowed another 1 mil into MPXI. I am considering opening an account with Haywood in Canada to have more access to Canadian and international stocks. Schwab makes it difficult to do so and we should be making noise on these international desks to bring them in line.

[Smoothsailor]

Schwab International Desk reports shares tradeable by Wed 20th at the latest. Only able to sell through them at this point. News anyone?

[nanook2]

Anyone know the market cap? It’s not showing on TD Ameritrade.

[Joecanada13]

Halfway there already